Listen Now

To mark National Mediterranean Diet Month, Dr. Nathaniel Chin discusses a recent National Institute on Aging-funded study that suggests the MIND and Mediterranean diets — both rich in vegetables, fruits, whole grains, olive oil, beans and fish — are associated with fewer signs of Alzheimer’s disease in the brains of older adults. In this special episode of Dementia Matters, Chin also revisits his interview with the creator of the MIND diet, Dr. Martha Clare Morris, shares recommendations for ten things to incorporate into your diet and five things to limit, and touches on the benefits of intermittent fasting. Show Notes This episode was uploaded as an exclusive video episode on the Wisconsin ADRC YouTube page on May 16, 2023. Watch the recording. Learn more about National Mediterranean Diet Month on our website. Read the National Institute on Aging’s press release, “MIND and Mediterranean diets linked to fewer signs of Alzheimer’s brain pathology,” published May 4, 2023. Listen to Dr. Martha Clare Morris’s episode of Dementia Matters, “MIND Diet for Healthy Brain Aging,” on our website. Listen to Dr. Remi Daviet’s episode of Dementia Matters, “Alcohol And The Brain: One Drink A Day Associated With Brain Shrinkage,” on our website. Listen to Dr. Mark Mattson’s episode of Dementia Matters, “Intermittent Fasting And Its Effects On The Brain,” on our website. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

Dr. Sarah Biber, the program director for the National Alzheimer’s Coordinating Center (NACC), joins the podcast to discuss efforts to increase representation and equitable practices across the 37 Alzheimer’s Disease Research Centers (ADRCs). She discusses key disparities in Alzheimer’s disease research, why diversity and inclusion are imperative in research, and what is being done to address these disparities with the data collected from research participants. This episode is the first of an upcoming series featuring speakers from the Fall 2022 ADRC Meeting, where the overarching theme was Diversity, Equity, and Inclusion (DEI) in ADRC research and operations.  Guest: Sarah Biber, PhD, program director, National Alzheimer’s Coordinating Center Show Notes Learn more information about the National Alzheimer’s Coordinating Center and watch the presentation recordings from the Spring ADRC Meeting on their website. Watch Dr. Biber’s presentation at the Fall ADRC Meeting, “Delivering on NACC’s Mission Through Modernization,” on YouTube. Watch Dr. Biber’s presentation at the Fall ADRC Meeting, “Amplifying the Scan Initiative,” on YouTube. Listen to Dr. Biber’s previous episode, “The Future Of Sharing And Accessing Alzheimer’s Disease Data,” on our website, or wherever you get your podcasts. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

Recorded live from the Wisconsin ADRC’s Alzheimer’s Disease & Related Dementias Research Day, Dr. Nathaniel Chin discusses the importance of mentorship and the future of neuroscience and Alzheimer’s disease research with the Alzheimer’s Association International Conference® (AAIC) Neuroscience Next 'One to Watch' award recipients and the event’s organizers. Guests: Barbara Bendlin, PhD, director, UW-Madison Neuroscience and Public Policy Program, leader, Research Education Component (REC), Wisconsin Alzheimer’s Disease Research Center; Claire Sexton, DPhil, senior director of scientific programs and outreach, Alzheimer’s Association; Nadia Dehghani, BS, co-chair, Neuroscience Next Scientific Program Committee; Claire André, PhD, postdoctoral fellow, Center for Advanced Research in Sleep Medicine, Université de Montréal; Chinmayi Balusu, founder, CEO, Simply Neuroscience; Kacie Deters, PhD, assistant professor, University of California Los Angeles; Kao Lee Yang, MPA/PhD candidate in the Neuroscience and Public Policy Program, University of Wisconsin–Madison Show Notes Learn more about Dr. Barbara Bendlin at her bio on our website. Learn more about Dr. Claire Sexton at her bio on the Alzheimer’s Association website. Learn more about Nadia Dehghani at her bio on the Van Andel Institute website. Learn more about Dr. Claire André, Chinmayi Balusu, Dr. Kacie Deters, and Kao Lee Yang at the press release, “Up-And-Coming Neuroscientists and Mentors Honored at Alzheimer’s Association International Conference Neuroscience Next,” on the Alzheimer’s Association website. Learn more about Chinmayi Balusu’s company, Simply Neuroscience, on their website. Learn more about AAIC Neuroscience Next at the Alzheimer’s Association website. Learn more about Alzheimer’s Disease & Related Dementias Research Day on the Wisconsin Alzheimer’s Disease Research Center’s website. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

Dr. Natascha Merten joins the podcast to discuss her study focused on trends in cognitive function across generations. Merten also explains her research on the associations between sensory and motor functions and blood-based biomarkers for neurodegeneration and dementia. Guest: Natascha Merten, PhD, MS, director, Beaver Dam Offspring Study-Neurocognitive Aging Study, assistant professor, Departments of Population Health Sciences and Medicine, University of Wisconsin–Madison Show Notes Read Dr. Merten’s studies, “Better cognitive function in younger generations - Insights from two cohort studies of middle-aged to older adults in Wisconsin,” and “Associations of sensory and motor function with blood-based biomarkers of neurodegeneration and Alzheimer's disease in midlife,” through ScienceDirect. Read Dr. Merten’s abstract from the 2022 Alzheimer’s Association’s International Conference through the journal Alzheimer’s & Dementia. Read about Dr. Merten’s R01 grant, “Dr. Natascha Merten Awarded NIA Funding To Study Sensory Changes Associated With Cognitive Change” on our website. Learn more about Dr. Merten in her bio on the University of Wisconsin Population Health Sciences website and on her Twitter @NataschaMerten. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

Dr. Annalise Rahman-Filipiak joins the podcast to discuss her research focused on disclosing neuroimaging biomarkers across diverse populations. She addresses why some people might want to know their biomarker results, while others might not, and how careful disclosure of these results to at-risk individuals may help prepare them and their families for the future through personalized treatment, research engagement, advanced planning and emotional support. Guest: Annalise Rahman-Filipiak, PhD, assistant professor, neuropsychologist, department of psychiatry, University of Michigan Show Notes Learn more about Dr. Rahman-Filipiak on the University of Michigan’s website. Read Dr. Rahman-Filipiak’s article, “Interest in and perceived benefits and risks of Alzheimer’s disease clinical and biomarker results disclosure among diverse participants and care partners,” at the journal Alzheimer’s & Dementia website. Follow Dr. Rahman-Filipiak on Twitter @RahFlipPhD. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

For families and dementia care partners, palliative care can help improve the quality of life for their loved ones and themselves by addressing physical and emotional needs. However, starting conversations around end-of-life care and planning can be difficult. Dr. Elizabeth Bukowy joins the podcast to explain the difference between palliative and hospice care, share how families and care partners can start these challenging conversations, and discuss why these discussions are essential for quality of life. Guest: Elizabeth Bukowy, DO, CMD, assistant professor, Medical College of Wisconsin Division of Geriatrics; medical director, Lutheran Home and Congregational Home Show Notes Learn more about the 20th Annual Update in Alzheimer’s Disease and Related Dementias on the Wisconsin Alzheimer’s Institute’s website. Watch the full keynotes of the event on our YouTube channel. Watch the pre-conference workshop for new dementia care professionals on our YouTube channel. Dr. Bukowy’s keynote starts at 1:46:46 in the recording. Learn more about Dr. Bukowy in her bio on Froedtert Hospital’s  website. Learn more about palliative care from our past episode, “Palliative Care And Hospice Conversations For Dementia Patients, Families And Caregivers.” Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

When seeking medical information and treatment, different racial and ethnic groups may require specially tailored information to relate to, understand and apply to their own experiences. In this episode, Dr. Fayron Epps joins the podcast to talk about the unique experiences of African American caregivers and her lab's work to provide education and assistance to their needs. Epps seeks to promote quality of life for families affected by dementia through research, education and service. This episode is part of a special three-part series highlighting speakers from the Wisconsin Alzheimer’s Institute’s 20th Annual Update in Alzheimer’s Research and Related Dementias. Guest: Fayron Epps, PhD, RN, FGSA, FAAN, assistant professor, Nell Hodgson Woodruff School of Nursing, Emory University, principal investigator, Faith Village Research Lab, founder, Alter Show Notes Learn more about the 20th Annual Update in Alzheimer’s Disease and Related Dementias on the Wisconsin Alzheimer’s Institute’s website. Watch the full keynotes of the event on our YouTube channel. Dr. Epps’ keynote starts at 1:13:37 in the recording. Learn more about Dr. Epps on Alter’s website. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

Mild cognitive impairment (MCI) is an emerging term in the field of Alzheimer’s disease and related dementias, characterized as the stage between the expected decline in memory and thinking that happens with age and the more severe decline of dementia. In this episode, Dr. Ronald Petersen joins the podcast to talk about how MCI compares to dementia, its many causes, and the impact of new lifestyle and drug interventions on its progression, as well as how his career led him to study Alzheimer's disease and MCI. This episode is part of a special three-part series highlighting speakers from the Wisconsin Alzheimer’s Institute’s 20th Annual Update in Alzheimer’s Disease and Related Dementias. Guest: Ronald C. Petersen, MD, PhD, director, Mayo Clinic Alzheimer's Disease Research Center, director, Mayo Clinic Study of Aging, Cora Kanow Professor of Alzheimer’s Disease Research, Mayo Clinic College of Medicine Show notes Learn more about the 20th Annual Update in Alzheimer’s Disease and Related Dementias on the Wisconsin Alzheimer’s Institute’s website. Watch the full keynotes of the event on our YouTube channel. Dr. Petersen’s keynote starts at 22:12 in the recording. Learn more about Dr. Petersen in his bio on his website. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

In a special episode of Dementia Matters, Drs. Cynthia Carlsson and Sterling Johnson join the podcast to discuss what they know from lecanemab’s clinical trials following the U.S. Food and Drug Administration’s (FDA) accelerated approval, granted on January 6, 2023. Guests: Cynthia Carlsson, MD, MS, director, Wisconsin Alzheimer’s Institute, and Sterling Johnson, PhD, leader, Wisconsin Registry for Alzheimer’s Prevention (WRAP), associate director, Wisconsin Alzheimer’s Disease Research Center and Wisconsin Alzheimer’s Institute Show Notes This episode was uploaded as an exclusive video episode on the Wisconsin ADRC YouTube page on February 13, 2023. Watch the video interview with Drs. Carlsson and Johnson here. In a previous episode of Dementia Matters, Dr. Chin gave a brief overview of lecanemab’s clinical trials. Listen to it on Spotify, Apple Podcasts, our website, or wherever you listen. Read more about the AHEAD study and A4 study at their respective websites. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

Former Governor of Wisconsin, Martin Schreiber, returns to Dementia Matters to discuss different methods for communicating with a loved one with Alzheimer’s disease, including therapeutic fibbing. Governor Schreiber has been a widely outspoken advocate for Alzheimer’s disease while caring for his late wife Elaine, who passed away from the disease in April of 2022. In this episode, he also talks about his book, My Two Elaines, where he opens up about his experience as a caregiver. Guest: Martin Schreiber, Former Governor of Wisconsin (1977-1979), Former Lt. Governor of Wisconsin (1971-1977) Show Notes Learn more about Martin Schreiber and his book, My Two Elaines, at his website, or follow him on Facebook. Listen to Governor Schreiber’s previous appearance on our website or wherever you get your podcasts.  Connect with us Find transcripts and more at our website. Email Dementia Matters Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

In October 2022, the Alzheimer's Association named Dr. Joanne Pike, the current president of the Association, as the next CEO, succeeding Harry Johns who has served as CEO since 2005. In this episode, Pike and Johns join the podcast to share their insights on how the Alzheimer's Association has grown over the past few decades and the future plans of the association, as well as the next steps in Alzheimer's treatment from both community and medication perspectives. Guests: Joanne Pike, DrPH, president and CEO, Alzheimer’s Association, Alzheimer’s Impact Movement, and Harry Johns, former CEO, Alzheimer's Association, former CEO and president, Alzheimer's Impact Movement (AIM), trustee and former chair, World Dementia Council Show Notes Learn more about CMS's updated coverage on monoclonal antibody treatment and the Alzheimer's Association’s response at their website. Learn more about Part the Cloud at their website. Learn more about the Alzheimer's Association at their website. Learn more about Dr. Pike in her bio on her website. Learn more about Mr. Johns in his bio on his website. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

Host Nathaniel Chin, MD, gives an overview of the new Alzheimer’s treatment Leqembi (lecanemab), and highlights results from the second and third phases of its clinical trials. On January 6, 2023, the U.S. Food and Drug Administration (FDA) approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway for the treatment of Alzheimer’s disease. Show Notes In the coming weeks, host Nathaniel Chin will be joined by Cynthia Carlsson, MD, MS, and Sterling Johnson, PhD, to further discuss lecanemab and the clinical trials’ results. A link to that episode will be added here following its release. Read the FDA’s news release regarding lecanemab’s accelerated approval on their website. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

Host Nathaniel Chin, MD, starts the new year by discussing modifiable risk factors for Alzheimer’s disease, commenting on building healthy lifestyle habits for the new year, and reflecting as Dementia Matters celebrates five years of production. Show Notes “Dementia prevention, intervention, and care: 2020 report of the Lancet Commission” is mentioned at the 4:16 mark. Read the full report on The Lancet’s website. Our past episode, “Alcohol and the Brain: One Drink a Day Associated with Brain Shrinkage,” is mentioned at the 5:05 mark. Listen on our website, Spotify, Apple Podcasts, or wherever you listen.  Our past episode, “Study Finds Air Pollution a Risk Factor For Alzheimer’s Disease,” is mentioned at the 5:07 mark. Listen on our website, Spotify, Apple Podcasts, or wherever you listen. Our past episode, “AARP Study Show Stigma Surrounding Dementia Among Healthcare Professionals And General Public,” is mentioned at the 5:28 mark. Listen on our website, Spotify, Apple Podcasts, or wherever you listen. As mentioned at the 7:40 mark, learn more about the books The Power of Habit by Charles Duhigg and Atomic Habits by James Clear, on the authors’ respective websites. Listen to our past episode, “Impacts of Exercise on Brain Health,” mentioned at the 9:37 mark. Learn about the book, Why Sleep Matters by Matthew Walker, mentioned at the 11:14 mark. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

It’s generally known that mitochondria are the powerhouse of cells, but did you know they can play a significant role in aging processes? Through the field of bioenergetics, scientists are looking to study how changes in mitochondria affect us as we age and their connection to Alzheimer’s disease. Dr. Russell Swerdlow joins the podcast to discuss the field of bioenergetics and how mitochondria can impact Alzheimer’s disease and other aspects of aging. Guest: Russell Swerdlow, MD, director, Kansas Alzheimer’s Disease Research Center, director, Heartland Center for Mitochondrial Medicine, professor of neurology, University of Kansas Show Notes Learn more about Dr. Russell Swerdlow at his bio on the University of Kansas Medical Center’s website. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

The field of biomarkers is advancing quickly, allowing preclinical Alzheimer’s disease to be identified earlier and earlier in a person’s life. As individuals learn they are at risk for Alzheimer’s years or even decades before experiencing cognitive decline, what does this mean for them and for society as a whole? Drs. Emily Largent and Claire Erickson join the podcast to discuss ten key areas, such as healthcare, insurance, and direct-to-consumer testing, that should be addressed to support those at risk for cognitive decline and broader U.S. society as biomarker testing and disclosures become more prominent. Guests: Emily Largent, PhD, RN, Emanuel and Robert Hart Assistant Professor, University of Pennsylvania Perelman School of Medicine, and Claire Erickson, PhD, MPA, postdoctoral fellow, University of Pennsylvania Perelman School of Medicine Show Notes Read Drs. Emily Largent and Claire Erickson’s paper, “Implications of preclinical Alzheimer's disease biomarker disclosure for US policy and society,” on PubMed Central.  Learn more about Dr. Largent at her bio on the Penn Leonard Davis Institute of Health Economics website. Learn more about Dr. Erickson at her bio on the Penn Leonard Davis Institute of Health Economics website. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

Though brain and cognitive changes are typically diagnosed as one form of dementia, recent studies have shown that mixed dementia is more common than previously thought. Mixed dementia, also known as Multiple-etiology dementia, is a condition where brain changes are caused by more than one neurological disease, such as Alzheimer’s disease, Lewy body dementia (LBD), or frontotemporal dementia. Dr. Roderick Corriveau joins the podcast to discuss what is known about mixed dementia and how the field of studying neurological diseases is advancing to diagnose and treat this condition. Guest: Roderick Corriveau, PhD, program director, National Institute of Neurological Disorders and Stroke (NINDS), NIH Lead, Alzheimer’s Disease-Related Dementias (ADRD) Summits Show Notes Read more about the National Institutes of Neurological Disorders and Stroke (NINDS) campaign, “Mind Your Risks,” at the Mind Your Risks website. Learn more about mixed dementia on the Alzheimer’s Association website. Learn more about Dr. Corriveau at his bio on the National Institutes of Neurological Disorders and Stroke website. Learn more about NINDS on their website. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

Though several validated biomarkers are studied and used in Alzheimer’s disease research, most research participants don’t have the opportunity to learn their biomarker results afterward, even if they have cognitive impairment. Drs. Jason Karlawish and Josh Grill join the podcast to discuss the debate over sharing biomarker results with research participants, how these powerful disclosures can be made ethically, and why it's as important for the field to study biomarker disclosures as it is to study the biomarkers themselves. Guests: Josh Grill, PhD, director, Institute for Memory Impairments and Neurological Disorders, associate professor, University of California, Irvine, and Jason Karlawish, MD, co-director, Penn Memory Center, professor of medicine, medical ethics and health policy, and neurology, University of Pennsylvania Show Notes Read Dr. Jason Karlawish and Dr. Josh Grill’s viewpoint piece, “Disclosing Alzheimer Disease Biomarker Results to Research Participants,” from JAMA Neurology’s June 2022 issue. Listen to our episode with Dr. Daniel Gibbs about his book (mentioned by Dr. Karlawish at 34:21) on our website, Spotify, Apple Podcasts, or wherever you listen. Listen to our past episode on amyloid disclosures with research participants on our website, Spotify, Apple Podcasts, or wherever you listen. Learn more about Dr. Josh Grill at his bio on the University of California - Irvine website. Learn more about Dr. Jason Karlawish’s work at his website. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

Dementia Matters Special Series: The National Strategy for Alzheimer's Disease Data and Research Part 6 Concluding our special series on the 2022 Spring ADRC Meeting, Dr. Cerise Elliott joins the podcast to discuss the NIA’s work within the field of Alzheimer’s disease research, how the NIA promotes open science to advance research across the ADRC program, and other key takeaways from the spring meeting. Guest: Cerise Elliott, PhD, program director for clinical interventions and diagnostics, division of neuroscience, National Institute on Aging Show Notes Watch Dr. Cerise Elliott’s session from the Spring ADRC Meeting, “Q&A with Program,” on NACC’s YouTube channel. Listen to our previous episode with Dr. Elliott, "National Priorities for Dementia and Health Disparities Research," on our website. Learn more about Dr. Elliott at her bio on the National Institute on Aging website. Learn more about the National Alzheimer’s Coordinating Center at their website. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

Dementia Matters Special Series: The National Strategy for Alzheimer's Disease Data and Research Part 5 Whether it be due to new research findings, innovative approaches and ideas, or technological advancements, Alzheimer’s disease research is constantly evolving. Now, dementia research is headed into the digital frontier. Dr. Rhoda Au joins the podcast to discuss digital biomarkers, gamifying cognitive testing, and how the field of Alzheimer’s disease research is entering its digital age. Guest: Rhoda Au, PhD, digital technology leader, Boston University Alzheimer’s Disease Research Center, co-principal investigator, director of neuropsychology, Framingham Heart Study, professor, Boston University School of Medicine Show Notes Watch Dr. Rhoda Au’s presentation from NACC’s Spring ADRC Meeting on NACC’s YouTube channel. Learn more about Dr. Au at her bio on the Boston University Chobanian & Avedisian School of Medicine website. Learn more about the National Alzheimer’s Coordinating Center at their website. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

Dementia Matters Special Series: The National Strategy for Alzheimer's Disease Data and Research Part 4 Brain imaging is a key tool in Alzheimer’s disease research and diagnoses, allowing scientists to see changes in the brain years, even decades, before an individual experiences symptoms of dementia. The data these images provide researchers with is incredibly useful, leading the National Alzheimer’s Coordinating Center to take up numerous efforts to standardize, unify and share this type of data across the Alzheimer’s Disease Research Centers. Dr. Beth Mormino joins the podcast to discuss the NIA’s SCAN initiative, the new “legacy” data set, and the importance of standardizing MRI and PET scan procedures to predict brain trajectories better. Guest: Beth Mormino, PhD, assistant professor, Stanford University Show Notes Learn more about Dr. Mormino’s presentation on the SCAN Legacy project by reading her presentation slides on NACC’s website. Listen to Dr. Mormino’s last episode on Dementia Matters, “The Science of Alzheimer’s Disease Risk,” on our website. Learn more about the National Alzheimer’s Coordinating Center at their website.  Register for NACC’s Fall 2022 ADRC Meeting on their website. Registration is free and open to the public. The fall meeting, which will focus on diversity, equity, and inclusion in Alzheimer’s research, will take place on Thursday, October 20, and Friday, October 21, virtually and in person in Chicago, IL. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.